Literature DB >> 6131079

Opposing actions of glucagon and insulin on splanchnic d cell function.

K Kawai, R H Unger.   

Abstract

The effect of glucagon at various infusion rates on plasma levels of somatostatin-like immunoreactivity (SLI) was examined in conscious normal and chronic alloxan diabetic dogs. In normal dogs glucagon infused at 6, 36, and 120 ng/kg per min did not affect the peripheral venous plasma SLI levels. In diabetic dogs, however, peripheral venous plasma SLI levels in inferior vena cava rose significantly from a mean base-line value of 181+/-9 pg/ml to a peak value of 279+/-38 pg/ml during the infusion of 120 mug/kg per min of glucagon, which raised plasma immunoreactive glucagon to >5,000 pg/ml. This glucagon-mediated increase was completely abolished by coinfusion of 7 mU/kg per min of insulin, a rate that maintained the ratio of insulin to glucagon at approximately the baseline value. In anesthetized normal dogs the concentration of SLI in the venous effluent of the pancreas, the gastric fundus and the antrum increased significantly with each infusion rate of glucagon using including the lowest rate of 4 ng/kg per min, which raised the plasma level of glucagon to 395+/-19 pg/ml. This stimulatory effect on SLI secretion was completely abolished by insulin coinfusion at a rate designed to maintain the insulin to glucagon ratio at approximately the baseline value, but the effect of a high 90-ng/kg per min infusion on pancreatic and gastric SLI release was not suppressed by coinfusion of 10 mU/kg per min insulin. These results suggest that glucagon stimulates splanchnic D cells unless insulin secretion is proportionally stimulated and suggests that the splanchnic D cell is a common target upon which the two hormones exert opposing actions. The loss of insulin inhibition of glucagon-mediated somatostatin secretion may account for the hypersomatostatinemia of severe diabetes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6131079      PMCID: PMC436922          DOI: 10.1172/jci110819

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

1.  Radioimmunoassay for GH-release inhibiting hormone.

Authors:  A Arimura; H Sato; D H Coy; A V Schally
Journal:  Proc Soc Exp Biol Med       Date:  1975-03

2.  A radioimmunoassay for growth hormone release-inhibiting hormone: method and quantitative tissue distribution.

Authors:  S Kronheim; M Berelowitz; B L Pimstone
Journal:  Clin Endocrinol (Oxf)       Date:  1976-11       Impact factor: 3.478

3.  Somatostatin release from isolated perfused rat stomach.

Authors:  T Chiba; Y Seino; Y Goto; S Kadowaki; T Taminato; H Abe; Y Kato; S Matsukura; M Nozawa; H Imura
Journal:  Biochem Biophys Res Commun       Date:  1978-05-30       Impact factor: 3.575

4.  Dynamics of somatostatin and insulin release from isolated rat pancreatic islets: evidence for intraislet interactions between B cells and D cells.

Authors:  P Schauder; C McIntosh; U Panten; J Arends; R Arnold; H Frerichs; W Creutzfeldt
Journal:  Metabolism       Date:  1978-09       Impact factor: 8.694

5.  Glucagon and the A cell: physiology and pathophysiology (first two parts).

Authors:  R H Unger; L Orci
Journal:  N Engl J Med       Date:  1981-06-18       Impact factor: 91.245

6.  The response of plasma somatostatin-like immunoreactivity to nutrients in normal and alloxan diabetic dogs.

Authors:  V Schusdziarra; D Rouiller; V Harris; J M Conlon; R H Unger
Journal:  Endocrinology       Date:  1978-12       Impact factor: 4.736

7.  Measurements of somatostatin-like immunoreactivity in plasma.

Authors:  V Harris; J M Conlon; C B Srikant; K McCorkle; V Schusdziarra; E Ipp; R H Unger
Journal:  Clin Chim Acta       Date:  1978-07-15       Impact factor: 3.786

8.  Pancreatic immunoreactive somatostatin release.

Authors:  G S Patton; E Ipp; R E Dobbs; L Orci; W Vale; R H Unger
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

9.  Pancreatic and gastric somatostatin release in response to intragastric and intraduodenal nutrients and HCl in the dog.

Authors:  V Schusdziarra; V Harris; J M Conlon; A Arimura; R Unger
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

10.  Free somatostatin in the circulation: amounts and molecular sizes of somatostatin-like immunoreactivity in portal, aortic, and vena caval plasma of fasting and meal-stimulated dogs.

Authors:  V Schusdziarra; E Zyznar; D Rouiller; V Harris; R H Unger
Journal:  Endocrinology       Date:  1980-11       Impact factor: 4.736

View more
  2 in total

1.  Basal alpha-cell up-regulation in obese insulin-resistant adolescents.

Authors:  Ram Weiss; Ebe D'Adamo; Nicola Santoro; Karen Hershkop; Sonia Caprio
Journal:  J Clin Endocrinol Metab       Date:  2010-09-15       Impact factor: 5.958

2.  Antecedent chronic hyperglycaemia blocks phlorizin-induced insulin resistance in the dog.

Authors:  M Koffler; T Imamura; F Santeusanio; J H Helderman
Journal:  Diabetologia       Date:  1988-04       Impact factor: 10.122

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.